BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17875803)

  • 21. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
    Tobinai K
    Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
    Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
    Laoruangroj C; Atherton PJ; Wiseman GA; Ansell S; Feldman AL; Schumacher P; Witzig TE
    Leuk Lymphoma; 2024 Mar; 65(3):333-338. PubMed ID: 38189774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody therapy of lymphoma.
    Illidge TM; Bayne MC
    Expert Opin Pharmacother; 2001 Jun; 2(6):953-61. PubMed ID: 11585011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
    Durando M; Gopal AK; Tuscano J; Persky D
    Oncologist; 2024 Apr; 29(4):278-288. PubMed ID: 38207010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
    J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
    Mondello P; Cuzzocrea S; Navarra M; Mian M
    Oncotarget; 2016 Feb; 7(7):7597-609. PubMed ID: 26657116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.
    Dillman RO
    Clin Exp Med; 2006 Mar; 6(1):1-12. PubMed ID: 16550338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
    Goldenberg DM
    Crit Rev Oncol Hematol; 2001; 39(1-2):195-201. PubMed ID: 11418316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma.
    White CA; Berlfein JR; Grillo-López AJ
    Curr Pharm Biotechnol; 2000 Dec; 1(4):303-12. PubMed ID: 11467328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
    J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates.
    Hopkins K; Chandler C; Bullimore J; Sandeman D; Coakham H; Kemshead JT
    Radiother Oncol; 1995 Feb; 34(2):121-31. PubMed ID: 7597210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.